Chuck Monahan
About Chuck Monahan
Charles Monahan is a seasoned regulatory affairs executive with over 20 years of experience in the pharmaceutical industry, specializing in oncology, infectious diseases, and ocular indications.
Charles Monahan: SVP Regulatory Affairs
Charles Monahan currently holds the title of Senior Vice President (SVP) Regulatory Affairs. He has accumulated extensive experience in regulatory affairs over the course of his notable career, specializing in the development of drugs and biologics for oncology, infectious diseases, and ocular indications.
Charles Monahan's Pharmacy and Regulatory Affairs Education
Charles Monahan earned a Bachelor of Science (BS) in Pharmacy from the University of Rhode Island. Following that, he obtained a Master of Science (MS) in Regulatory Affairs and Health Policy from the Massachusetts College of Pharmacy and Health Sciences. His educational background has provided a strong foundation for his career in regulatory affairs.
Charles Monahan's Regulatory Affairs Expertise
With over 20 years of experience in regulatory affairs, Charles Monahan has played a critical role in developing drugs and biologics across various therapeutic areas, including oncology, infectious diseases, and ocular indications. His deep expertise in regulatory requirements and policy has been pivotal in successfully navigating complex regulatory landscapes.
Charles Monahan's Professional Background
Charles Monahan has held several senior regulatory positions at prominent pharmaceutical companies. He served as the Global Head of Regulatory Affairs for Erytech PharmaSA. Additionally, he held key roles at Millennium Pharmaceuticals, Molecular Insight Pharmaceuticals, AVEO Pharmaceuticals, and Transgene SA. His extensive experience spans both strategic and operational aspects of regulatory affairs.
Charles Monahan: Registered Pharmacist
Charles Monahan is a registered pharmacist. His background in pharmacy, combined with his extensive regulatory experience, allows him to approach drug development and regulatory challenges with a comprehensive perspective, ensuring both scientific and regulatory considerations are addressed.